Neurocrine Biosciences (NBIX)
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the...
- Open
- 157.195
- High
- 159.670
- Low
- 156.120
- Prev. Close
- 156.570
- Volume
- 890.88K
- Turnover
- 139.68M
- Avg Price
- 156.789
- Bid/Ask Ratio
- -87.88%
- Amplitude
- 2.27%
- 52wk High
- 186.120
- Volume Ratio
- 0.75
- Turnover Ratio
- 0.89%
Neurocrine Biosciences Analyst Rating
View moreForecast & Rating
Sep 11, 2026Price forecast
$210.7934.93%
Forecast & RatingStrong buy
27analysts
- Strong buy70.37%
- Buy14.81%
- Hold14.81%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 06:12 PM
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says
- PUBT · Sep 11 at 12:29 AM
Neurocrine Chief Commercial Officer Eric Benevich disposes of 2,154 common shares worth $333,428.94
- Quartr · Sep 10 at 02:08 PM
NBIX: Multi-product growth, robust pipeline, and strategic adaptation position for long-term success
- Market Beat · Sep 8 at 03:24 PM
Neurocrine Biosciences' (NBIX) "Outperform" Rating Reiterated at Royal Bank Of Canada
- Market Beat · Sep 7 at 06:29 AM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts
- PUBT · Sep 2 at 08:01 PM
Neurocrine Biosciences executives to speak at Wells Fargo healthcare conference
